|
Tuesday 23rd February 2016 |
Text too small? |
New Zealand life science and medical research companies will be able to bid for millions of Australian dollars in funding to support new drugs and medical developments after the government signed up to Australia's Medical Research Commercialisation Fund.
New Zealand will pay A$500,000 a year to be part of the fund, the same amount paid by Australian states, Science and Innovation Minister Steven Joyce said in a statement. The fund was set up in 2007 and other investors include Australian Superannuation funds. It is operated by Brandon Capital Partners.
Companies compete for investment and support for the pre-clinical development and commercialisation of discoveries. Early funding can receive up to A$3 million, with the potential for a further A$17 million in investment.
Joyce said the deal was vital in attracting high quality business investment to New Zealand: "Since 2007, the MRCF has supported the development of 24 start-up companies, with some notable successes, such as Spinifex Pharmaceuticals, which sold this year for over US$700 million, and Fibrotech Therapeutics, which netted US$557 million in 2014.”
Ideas and developments are chosen on whether they represent significant breakthroughs, the size and scale of potential markets and the strength of the intellectual property.
BusinessDesk.co.nz
No comments yet
SKT - Sky ASM - Q1 Dividend Announced and Guidance Reiterated
TRA - Turners absorbs oil shock to deliver a record first half
Devon Funds Morning Note - 20 November 2026
IFT - Lodgement of Product Disclosure Statement for Capital Bond
LOD - Lodestone Energy delivers strong growth
FSF - Fonterra increases FY27 forecast Farmgate Milk Price
November 20th Morning Report
RGI - Reefton Resource Update and PFS
Devon Funds Morning Note - 19 November 2026
RYM - Ryman appoints two new directors